abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

18 Jul 2008

Author:
Indo Asian News Service

Indian firms, Clinton Foundation sign deal on malaria drugs

Four Indian and two Chinese companies will cut the price of a key malaria drug and control rates of a vital ingredient following a pact signed Thursday with the US-based Clinton Foundation…The Indian companies are generic drug firms Cipla and IPCA Laboratories… and Calyx and Mangalam Drugs…China’s Holleypharm and PIDI Standard grow the plants…“This agreement will reduce the prices for ACT drugs by 30 percent,” [former U.S. President Bill] Clinton said while announcing the deal...The lower prices for the ACT drugs will be available to the 69 countries in Africa, Asia, Latin America and the Caribbean that make up the Clinton HIV-AIDS Initiative (CHAI) purchasing consortium…[refers also to Novartis]

Timeline